
    
      Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for
      borderline resectable cholangiocarcinoma.

      This study is a single center prospective phase II study of neoadjuvant chemotherapy with
      mFOLFOXIRI in patients with borderline resectable cholangiocarcinoma.

      This phase 2 trial was designed to enroll 25 patients with BRCC who were assigned to
      mFOLFOXIRI neoadjuvant chemotherapy. The primary endpoint was the overall response rate.
    
  